Dr. Rana McKay

And are you actually impacting their survival in any way by giving them the two or four weeks of biclutamide? So I think, you know, not to say that there's been a movement away, but I think we are seeing less utilization of the first generation antiandrogens in the clinic because of the fact that we have these next generation agents and many individuals are getting such agents.

And are you actually impacting their survival in any way by giving them the two or four weeks of biclutamide? So I think, you know, not to say that there's been a movement away, but I think we are seeing less utilization of the first generation antiandrogens in the clinic because of the fact that we have these next generation agents and many individuals are getting such agents.

I don't feel so strongly that somebody must absolutely get biclutamide to suppress the T-flare. I think in the localized context, where I'm not using an ARSI, then I will absolutely do that.

I don't feel so strongly that somebody must absolutely get biclutamide to suppress the T-flare. I think in the localized context, where I'm not using an ARSI, then I will absolutely do that.

I don't feel so strongly that somebody must absolutely get biclutamide to suppress the T-flare. I think in the localized context, where I'm not using an ARSI, then I will absolutely do that.

But when I am using an ARSI, I think it just gets very complicated for the patients to also have to worry about getting their first generation antiandrogen while we're getting their Abby on board or Enza on board. You know, we may just tell them to start their Abby or Enza first and then come in later for the injection. So at the end of the day, do I think that that impacts overall survival? No.

But when I am using an ARSI, I think it just gets very complicated for the patients to also have to worry about getting their first generation antiandrogen while we're getting their Abby on board or Enza on board. You know, we may just tell them to start their Abby or Enza first and then come in later for the injection. So at the end of the day, do I think that that impacts overall survival? No.

But when I am using an ARSI, I think it just gets very complicated for the patients to also have to worry about getting their first generation antiandrogen while we're getting their Abby on board or Enza on board. You know, we may just tell them to start their Abby or Enza first and then come in later for the injection. So at the end of the day, do I think that that impacts overall survival? No.

I do. You know, I've actually, I do run through the side effects because I think at the end of the day, patients want to know, And I hate it when somebody comes back in the clinic and they're like, nobody ever told me this was going to happen. So I really want patients to be informed about the side effects that they may experience and the different things that may happen.

I do. You know, I've actually, I do run through the side effects because I think at the end of the day, patients want to know, And I hate it when somebody comes back in the clinic and they're like, nobody ever told me this was going to happen. So I really want patients to be informed about the side effects that they may experience and the different things that may happen.

I do. You know, I've actually, I do run through the side effects because I think at the end of the day, patients want to know, And I hate it when somebody comes back in the clinic and they're like, nobody ever told me this was going to happen. So I really want patients to be informed about the side effects that they may experience and the different things that may happen.

And we certainly can't go through every little possible thing that could certainly happen. But I think it's key to go through the key ones that you're worried about when starting ADT. And I think it's important because then you can help with prevention. So that's going to be key. So I think the first thing is kind of going through the fatigue side effects.

And we certainly can't go through every little possible thing that could certainly happen. But I think it's key to go through the key ones that you're worried about when starting ADT. And I think it's important because then you can help with prevention. So that's going to be key. So I think the first thing is kind of going through the fatigue side effects.

And we certainly can't go through every little possible thing that could certainly happen. But I think it's key to go through the key ones that you're worried about when starting ADT. And I think it's important because then you can help with prevention. So that's going to be key. So I think the first thing is kind of going through the fatigue side effects.

Many patients want to know, am I going to be able to continue working? Am I going to be able to continue exercising? And so kind of level setting is important around there. The vasomotor symptoms, I think, are really important to describe.

Many patients want to know, am I going to be able to continue working? Am I going to be able to continue exercising? And so kind of level setting is important around there. The vasomotor symptoms, I think, are really important to describe.

Many patients want to know, am I going to be able to continue working? Am I going to be able to continue exercising? And so kind of level setting is important around there. The vasomotor symptoms, I think, are really important to describe.

You know, the other thing that I think is really important is the sexual side effects and not just with regards to libido, but the body dysmorphism that can happen from going on ADT. I think patients want to know that. And not be like, what is happening to me?

You know, the other thing that I think is really important is the sexual side effects and not just with regards to libido, but the body dysmorphism that can happen from going on ADT. I think patients want to know that. And not be like, what is happening to me?

You know, the other thing that I think is really important is the sexual side effects and not just with regards to libido, but the body dysmorphism that can happen from going on ADT. I think patients want to know that. And not be like, what is happening to me?